# Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD

> **NCT01835067** · PHASE2,PHASE3 · COMPLETED · sponsor: **King's College Hospital NHS Trust** · enrollment: 55 (actual)

## Conditions studied

- Exudative Macular Degeneration
- Retinal Hemorrhage

## Interventions

- **DRUG:** Ranibizumab
- **DRUG:** C3F8 Gas
- **DRUG:** tPA

## Key facts

- **NCT ID:** NCT01835067
- **Lead sponsor:** King's College Hospital NHS Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2019-11
- **Final completion:** 2019-12
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2020-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01835067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01835067, "Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01835067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*